houston innovators podcast episode 123

Houston innovator: The future of decarbonization is data-driven decision making

Sujatha Kumar discusses her decarbonization data company on this week's episode of the Houston Innovators Podcast. Photo via LinkedIn

Decarbonizing the energy industry would be a lot more successful if companies had the tools to more efficiently and accurately track their carbon footprint.

Sujatha Kumar has created that tool with her startup Dsider, a decision intelligence platform with a suite of software tools to equip energy businesses with the data they need to make informed decisions. Kumar, founder and CEO, has spent years consulting companies on finding operational success and now is using her Dsider platform to streamline results.

"When I looked at how companies made decisions — especially in the decarbonization world — I realized there was a big gap to be filled, and that's how Dsider was born," Kumar says on the Houston Innovators Podcast.

"We are creating transparency so that companies can have a digital footprint of how decarbonization can happen, and allowing them to make decisions along the way that are always going to be towards decarbonation and not forgetting that everything has an economic trade off," she continues.

Dsider, a Greentown Houston member company, is targeting the energy industry specifically — oil and gas, petrochemicals, utilities, etc. She says Dsider has the potential to bring decarbonization decision making to other industries as well. For now, Dsider has a few customers and is actively seeking out a few more.

"One of the first few things we want to do is get traction with a handful of customers," "We have the rigor and we are able to make sure the products we have brought to market are really something that is going to land well with customers. From that, we want to see the growth accelerator."

This year, Kumar hopes raise seed funding and grow her team and customer base. She still is working with companies as a consultant with her business, Ayatis LLC. She says the two roles go hand in hand — Dsider is a tool she can offer her consultancy clients.

"We live in that world today where a single role isn't enough for us," Kumar says. "The consulting angle has really helped me think through the customer journey. ... That has really created the Dsider and product journey. In order for me to grow Dsider, I can't balance the consulting that I used to do, so all of my consulting will be geared towards helping customers decarbonize and leveraging Dsider to do that."

Kumar shares more on Dsider's potential impact on decarbonization and how she has observed changes in Houston's innovation ecosystem on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted